SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
BCYC

Bicycle Therapeutics PLC (NASDAQ:BCYC)

GB · Delayed Price · Currency is USD
Healthcare · Biotechnology
$2.90-$0.15 (-4.92%)
 
Market cap
$203M
Insider Score
Health Score
Analyst consensus
Listed since
May 23, 2019
Market Cap$202.98M-57.0%
Revenue (ttm)$83.53M+194.7%
Net Income-$141.79M+43.4%
EPS-$2.03+43.8%
Shares Out69.99M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,023,517
Open$2.98
Previous Close$3.05
Day's Range$2.85 - $2.98
52-Week Range$2.85 - $7.83
Beta1.60
AnalystsBuy
Price Target$10.00(+244.83%)
Earnings DateMar 16, 2027

About BCYC

Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeutic areas like anti-infectives, cardiovascular conditions, ophthalmology, and respiratory illnesses. Notable partnerships include a clinical trial and license agreement with Cancer Research Technology Limited and Cancer Research UK. They also maintain research collaborations with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund. Furthermore, a significant discovery collaboration and license agreement with Genentech is in place for the identification and development of Bicycle peptides for multiple immuno-oncology targets.

Address
Portway Building, Cambridge, CAM, CB21 6GS, GB
Market Cap
203 million
Employees
288
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$125.95K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From BCYC’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-4.92%
5 Days
-12.91%
1 Month
-20.33%
6 Months
-36.26%
1 Year
-56.97%

$BCYC stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in BCYC holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by BCYC's directors and management

Net Shares Purchased by Insiders−20k−10k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

BCYC Estimated quarterly lobbying spending

Source: U.S. Senate LDA

BCYC Revenue by Segment or Geography

BCYC's latest filing doesn't break out revenue by segment.

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New BCYC patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to BCYC from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in BCYC

IBBiShares Biotechnology ETF$840.02K
BBCVirtus Biotech Clinical Trials ETF$201.05K
SBIOALPS Medical Breakthroughs ETF$178.12K
GWXState Street SPDR S&P International Small Cap ETF$116.94K
QQQSInvesco NASDAQ Future Gen 200 ETF$89.38K
APIEActivePassive International Equity ETF$59.28K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from BCYC’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
85
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
27
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BBCVirtus Biotech Clinical Trials ETF0.67%
QQQSInvesco NASDAQ Future Gen 200 ETF0.51%
MEDXHorizon Kinetics Medical ETF0.22%
SBIOALPS Medical Breakthroughs ETF0.11%
PEPTREX Peptide ETF0.08%
IBBQInvesco Nasdaq Biotechnology ETF0.01%
IBBiShares Biotechnology ETF0.01%
BIBProShares Ultra Nasdaq Biotechnology0.01%
APIEActivePassive International Equity ETF0.01%

Weight is the stock’s share of each fund’s holdings.